Home > Insider Trading > Filing (0001144204-19-034764)

Filing Details

Accession Number:: 0001144204-19-034764
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-07-15 20:38:25
Reporting Period:: 2019-07-11

Accepted Time:: 2019-07-15 20:38:25
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1372514	Eyegate Pharmaceuticals Inc	EYEG	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1669087	Barbara Wirostko	C/O Eyegate Pharmaceuticals, Inc. 271 Waverley Oaks Road, Suite 108 Waltham MA 02452	Chief Medical Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2019-07-11	6,487	$0.24	418,510	No	4	S	Direct
Common Stock	Disposition	2019-07-12	6,488	$0.24	412,022	No	4	S	Direct
Common Stock	Disposition	2019-07-15	6,488	$0.23	405,534	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	59,915	Indirect	By husband

Footnotes

Sale of shares to cover taxes due on restricted stock that vested on 07/10/2019.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.24 to $0.245, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.2257 to $0.24, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.227 to $0.2403, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4.